Ontology highlight
ABSTRACT: Background
Entecavir (ETV) is a deoxyguanosine analog competitive inhibitor of hepatitis B virus (HBV) polymerase that exhibits delayed chain termination of HBV DNA. A high barrier to entecavir-resistance (ETVr) is observed clinically, likely due to its potency and a requirement for multiple resistance changes to overcome suppression. Changes in the HBV polymerase reverse-transcriptase (RT) domain involve lamivudine-resistance (LVDr) substitutions in the conserved YMDD motif (M204V/I +/- L180M), plus an additional ETV-specific change at residues T184, S202 or M250. These substitutions surround the putative dNTP binding site or primer grip regions of the HBV RT.Methods/principal findings
To determine the mechanistic basis for ETVr, wildtype, lamivudine-resistant (M204V, L180
SUBMITTER: Walsh AW
PROVIDER: S-EPMC2820545 | biostudies-literature | 2010 Feb
REPOSITORIES: biostudies-literature